Johannes Hausmann1, Astrid Waechtershaeuser2, Imke Behnken3, Aysegül Aksan4, Irina Blumenstein5, Michael Brenner3, Stefan M Loitsch2, Juergen Stein3. 1. 1st Med. Department, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, Germany. Electronic address: johannes.hausmann@kgu.de. 2. 1st Med. Department, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, Germany. 3. Dpt. Gastroenterology and Clinical Nutrition, DGD Clinics Frankfurt-Sachsenhausen, Germany; Obesity Centre Frankfurt, Schifferstrasse 59, Frankfurt am Main Germany. 4. Dpt. Gastroenterology and Clinical Nutrition, DGD Clinics Frankfurt-Sachsenhausen, Germany; Obesity Centre Frankfurt, Schifferstrasse 59, Frankfurt am Main Germany; Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. 5. 1st Med. Department, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, Germany; Obesity Centre Frankfurt, Schifferstrasse 59, Frankfurt am Main Germany.
Abstract
BACKGROUND: Obesity is an independent risk factor for cardiovascular disease and diabetes weight reduction not only reduces the risk for these diseases but leads to an alteration of the circulating adipokine levels. The aim of our study was to evaluate the effect of weight loss and lifestyle changes implemented in the form of the interdisciplinary weight management programme Optifast52® on cardiovascular and diabetic risk factors and on key adipokines. METHODS: 72 morbidly obese patients were included in the programme, which consisted of a very low-calorie diet followed by incremental food introduction and dietary stabilisation, accompanied by medical surveillance, physical activity, dietary counselling and psychological support. At baseline, and after 14, 26 and 49 weeks, risk factor profiles and adipokine levels were evaluated. RESULTS: 43 patients completed the programme with an average weight reduction of about 20%. Significant improvement was observed in the lipid and diabetic laboratory panels of all patients. In addition, adiponectin levels increased significantly (7.79 vs. 12.38μg/ml, p<0.001), while leptin levels decreased (7.29 vs 3.09ng/ml, p<0.001) during the course of the programme. CONCLUSION: In this study, Optifast52®, a multidisciplinary programme focusing on diet and lifestyle changes, was found not only to affect a decrease in parameters associated with diabetes and cardiovascular disease, but also to ameliorate in part the obesity-related imbalance of pro- and anti-inflammatory adipokines.
BACKGROUND:Obesity is an independent risk factor for cardiovascular disease and diabetes weight reduction not only reduces the risk for these diseases but leads to an alteration of the circulating adipokine levels. The aim of our study was to evaluate the effect of weight loss and lifestyle changes implemented in the form of the interdisciplinary weight management programme Optifast52® on cardiovascular and diabetic risk factors and on key adipokines. METHODS: 72 morbidly obesepatients were included in the programme, which consisted of a very low-calorie diet followed by incremental food introduction and dietary stabilisation, accompanied by medical surveillance, physical activity, dietary counselling and psychological support. At baseline, and after 14, 26 and 49 weeks, risk factor profiles and adipokine levels were evaluated. RESULTS: 43 patients completed the programme with an average weight reduction of about 20%. Significant improvement was observed in the lipid and diabetic laboratory panels of all patients. In addition, adiponectin levels increased significantly (7.79 vs. 12.38μg/ml, p<0.001), while leptin levels decreased (7.29 vs 3.09ng/ml, p<0.001) during the course of the programme. CONCLUSION: In this study, Optifast52®, a multidisciplinary programme focusing on diet and lifestyle changes, was found not only to affect a decrease in parameters associated with diabetes and cardiovascular disease, but also to ameliorate in part the obesity-related imbalance of pro- and anti-inflammatory adipokines.
Authors: Mohammed Faraz Rafey; Razk Abdalgwad; Paula Mary O'Shea; Siobhan Foy; Brid Claffey; Colin Davenport; Derek Timothy O'Keeffe; Francis Martin Finucane Journal: Front Nutr Date: 2022-05-18